Current targeting strategies and advanced nanoplatforms for atherosclerosis therapy
- PMID: 38217526
- DOI: 10.1080/1061186X.2023.2300694
Current targeting strategies and advanced nanoplatforms for atherosclerosis therapy
Abstract
Atherosclerosis is one of the major causes of death worldwide, and it is closely related to many cardiovascular diseases, such as stroke, myocardial infraction and angina. Although traditional surgical and pharmacological interventions can effectively retard or slow down the progression of atherosclerosis, it is very difficult to prevent or even reverse this disease. In recent years, with the rapid development of nanotechnology, various nanoagents have been designed and applied to different diseases including atherosclerosis. The unique atherosclerotic microenvironment with signature biological components allows nanoplatforms to distinguish atherosclerotic lesions from normal tissue and to approach plaques specifically. Based on the process of atherosclerotic plaque formation, this review summarises the nanodrug delivery strategies for atherosclerotic therapy, trying to provide help for researchers to understand the existing atherosclerosis management approaches as well as challenges and to reasonably design anti-atherosclerotic nanoplatforms.
Keywords: Atherosclerosis; biomimetic nanoparticles; drug delivery; membrane.
Similar articles
-
Platelet membrane-coated nanoparticle-mediated targeting delivery of Rapamycin blocks atherosclerotic plaque development and stabilizes plaque in apolipoprotein E-deficient (ApoE-/-) mice.Nanomedicine. 2019 Jan;15(1):13-24. doi: 10.1016/j.nano.2018.08.002. Epub 2018 Aug 30. Nanomedicine. 2019. PMID: 30171903
-
Non-proinflammatory and responsive nanoplatforms for targeted treatment of atherosclerosis.Biomaterials. 2017 Oct;143:93-108. doi: 10.1016/j.biomaterials.2017.07.035. Epub 2017 Jul 29. Biomaterials. 2017. PMID: 28778000
-
Targeting the Microenvironment of Vulnerable Atherosclerotic Plaques: An Emerging Diagnosis and Therapy Strategy for Atherosclerosis.Adv Mater. 2022 Jul;34(29):e2110660. doi: 10.1002/adma.202110660. Epub 2022 May 29. Adv Mater. 2022. PMID: 35238081 Review.
-
Pharmacological modulation of cell death in atherosclerosis: a promising approach towards plaque stabilization?Br J Pharmacol. 2011 Sep;164(1):1-13. doi: 10.1111/j.1476-5381.2011.01342.x. Br J Pharmacol. 2011. PMID: 21418184 Free PMC article. Review.
-
High-density lipoprotein-based nanoplatforms for macrophage-targeted diagnosis and therapy of atherosclerosis.Int J Biol Macromol. 2025 May;306(Pt 3):140826. doi: 10.1016/j.ijbiomac.2025.140826. Epub 2025 Feb 24. Int J Biol Macromol. 2025. PMID: 40010459 Review.
Cited by
-
Bioactive Macromolecule-mediated Biogenic FeONPs Attenuate Inflammation in Atherosclerotic Rat by Activating PI3K/Akt/eNOS Pathway.Curr Pharm Des. 2025;31(11):843-854. doi: 10.2174/0113816128298009240828062231. Curr Pharm Des. 2025. PMID: 39317998
-
Advancements in the Treatment of Atherosclerosis: From Conventional Therapies to Cutting-Edge Innovations.ACS Pharmacol Transl Sci. 2024 Dec 4;7(12):3804-3826. doi: 10.1021/acsptsci.4c00574. eCollection 2024 Dec 13. ACS Pharmacol Transl Sci. 2024. PMID: 39698263 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical